Crockett Thomas Andrew 4
4 · KalVista Pharmaceuticals, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Crockett Thomas Andrew
DirectorPresident and CEO
Transactions
- Award
Performance Stock Units
2024-02-11+83,333→ 83,333 total→ Common Stock (83,333 underlying) - Award
Common Stock
2024-02-11+122,500→ 240,032 total
Footnotes (3)
- [F1]Shares earned upon the vesting of a percentage of the performance stock units ("PSUs") granted to the Reporting Person on March 11, 2022. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of performance data metric goals ("Performance Metrics"). 100% of the total number of shares subject to the PSUs vested on February 11, 2024, upon Performance Metrics achieved.
- [F2]Each PSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F3]Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on January 10, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Metrics. 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of February 17, 2024, upon Performance Metrics achieved, subject to continued service through each vesting date.